Louise Emmett

16PUBLICATIONS
151CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmacogenomicsCancer geneticsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 07, 2026
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.

|Apr 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Apr 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Feb 06, 2026
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

Aslı D Munzur, Cameron Herberts, Edmond M Kwan

|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.

Edmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer

Pageof 3

Frequent Collaborators

6 joint publications

Matthew J Roberts

6 joint publications

Michael S Hofman

5 joint publications

Ian D Davis

4 joint publications

Andrew Morton